Nevertheless, it seems that selective inhibition of PI3Ks, especially p110δ in MDSCs, may promise a targeted approach to modulate the immunosuppressive TME, potentially enhancing anti-tumor immunity and improving the efficacy of cancer immunotherapies. Here, PIK3CD is linked to neoplasm.